Synergy Pharmaceuticals’ Plecanatide Phase 2b Trial in IBS-C Reaches
Enrollment Halfway Mark
NEW YORK -- July 17, 2013
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a developer of new drugs to treat
gastrointestinal diseases and disorders, today announced that it has reached
the halfway mark for total enrollment in its ongoing plecanatide Phase 2b
clinical trial in patients with irritable bowel syndrome with constipation
The study is being conducted at 70 sites in the United States and is scheduled
to include 350 patients with IBS-C. Over 600 patients have been screened to
date and 180 have been enrolled. The first patient was dosed on December 27,
2012 and Synergy anticipates completing enrollment in the fourth quarter of
2013 and reporting topline data in the first quarter of 2014.
The trial, entitled, “A randomized, 12-Week, Double-Blind, Placebo-Controlled,
Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in
Patients with Irritable Bowel Syndrome with Constipation,”
includes four doses of plecanatide (0.3,1.0,3.0,9.0 mg) plus a placebo arm,
taken once daily over a period of 12-weeks.
Plecanatide IBS-C Study Design
Patients must meet modified Rome III criteria for IBS-C as demonstrated by a
history of recurrent abdominal pain or discomfort covering at least 3
days/month in the last 3 months associated with two or more of: 1) improvement
with defecation, 2) onset associated with a change in frequency of stool, and
3) onset associated with a change in form (appearance) of stool. Patients must
also meet the criteria for the IBS-C subtype, which is further characterized
by stool pattern, such that ≥ 25% of defecations are hard or lump stools and ≤
25% of defecations are loose or watery stools. During pre-treatment, baseline
patients are required to have at least 3 days in each week with pain scores ≥
3 on a 0 to 10 scale.
The IBS-C trial will measure the mean change in CSBMs over the 12-week
treatment period relative to patient’s baseline weekly CSBM rate established
during the screening phase of the study. The study will also evaluate
spontaneous bowel movements (SBMs) and daily abdominal pain, discomfort and
bloating scores as well as the impact of plecanatide on disease-specific
quality of life measures.
Plecanatide is Synergy’s lead guanylate cyclase-C (“GC-C”) agonist in
development to treat patients with chronic idiopathic constipation (CIC) and
irritable bowel syndrome with constipation (IBS-C) disorders. Plecanatide is a
proprietary analog of uroguanylin, a hormone the body naturally produces to
regulate critical GI functions. Orally administered plecanatide, like
uroguanylin, binds to and activates the GC-C receptor expressed in the GI
tract, resulting in fluid secretion and normalization of bowel movement.
Plecanatide has successfully completed a Phase 2a trial and a large
multicenter trial in patients with CIC.
About Synergy Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy’s lead drug, plecanatide, and next generation
candidate, SP-333, are proprietary analogs of the natural human GI hormone,
uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”)
agonists. Plecanatide is currently in development for the treatment of chronic
idiopathic constipation (CIC) and irritable bowel syndrome with constipation
(IBS-C). Synergy has successfully completed a positive Phase 2a trial and a
large multicenter clinical trial of plecanatide in patients with CIC. SP-333
is in development to treat patients with inflammatory bowel diseases and other
GI conditions. More information is available at www.synergypharma.com
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward- looking words such as
"anticipate," "planned," "believe," "forecast," "estimated," "expected," and
"intend," among others. These forward-looking statements are based on
Synergy's current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government
or third party payer reimbursement; limited sales and marketing efforts and
dependence upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in the
development, regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this press release
will be completed or successful or that any product will receive regulatory
approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Form 10-K for the year
ended December 31, 2012 and other periodic reports filed with the Securities
and Exchange Commission. While the list of factors presented here is
considered representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted factors may
present significant additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as of the date
hereof, and Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Synergy Pharmaceuticals Inc.
Gem Gokmen, 212-584-7610
Bernard Denoyer, 212-297-0020
Press spacebar to pause and continue. Press esc to stop.